logo_web
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet
✕
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet

2019, a new year of “progress” and “remarkable progress” for pharmaceutical innovation

The European agency EMA gives green light to 30 new drugs and the US FDA, to 48
Hematology and oncology account for more than a third of the new approvals, and almost one in four are therapies for rare diseases

Source: www. farmaindustria.es

The European Medicines Agency (EMA) has released on Thursday its annual report on the main developments in the field of drug approval, in which it recalls that “advances in drug authorizations are essential for the progress of public health, since they provide new opportunities to treat certain diseases ”, and that reveals that in 2019 it gave the green light to 30 completely new drugs and issued a total of 66 positive opinions. With this data, Europe has approved 173 new medicines in the last 5 years, reflecting the research effort of the pharmaceutical industry to respond to millions of patients.

In 2019, the area that has most monopolized has been hematology, followed by cancer, infectious and endocrinology, although European specialists in neurology, ophthalmology, cardiovascular, metabolism, rheumatology, psychiatry and dermatology have also increased their therapeutic arsenal.

In addition, the regulatory authority has approved a new vaccine in the exercise that has just ended. This is the first immunization against Ebola, a serious disease that can reach mortality rates of 90%. Precisely this vaccine is one of the 8 new products that the EMA highlights in its report for having supposed “significant progress in its therapeutic areas”. In this selection there are also two drugs for diabetes.

Protagonism of orphan drugs

Of the 30 developments it is important to underline that seven (almost one in four) are therapies considered orphaned, which once again highlights the commitment of the innovative pharmaceutical industry to the area of ??rare or rare diseases, a constant demand among Patient associations Also, among this thirty new substances highlights a new therapy considered “advanced”, this time to treat patients with beta thalassemia.

With regard to the type of authorization procedure, it should be stressed that a third of the new medicines have been approved by special evaluation schemes: expedited, conditional processing or under exceptional circumstances in response to unmet medical needs.

FDA activity

In the same positive sense, the US regulatory agency, FDA, whose Drug Evaluation and Research Center (CDER) considers the 48 new drugs approved in 2019 to be a remarkable advance this week.

And the FDA has also made public this week its approval data, somewhat above the European figures, but also the area of ??hematology and oncology and the innovative response in rare diseases.

“More important than the amount of new therapies is their medical value and the new roles that these medications are fulfilling to advance patient care,” values ??the New Drug Therapy Approvals 2019 report. Advancing Health Through Innovation.

In Distefar we support this type of actions. The pharmaceutical industries are essential in terms of research and advances to treat certain diseases.

Related entries

4 October, 2023

“Artificial intelligence and technology are driving digital therapies, which benefit not only patients, but the healthcare system and society as a whole”.


Leer más
2 October, 2023

Decentralisation of trials, networking and digitisation, proposals to improve patient participation in clinical research


Leer más
26 September, 2023

More than 120 molecules in Alzheimer’s research, the great hope for patients, families and society


Leer más

Recent Posts

  • “Artificial intelligence and technology are driving digital therapies, which benefit not only patients, but the healthcare system and society as a whole”.
  • Decentralisation of trials, networking and digitisation, proposals to improve patient participation in clinical research
  • More than 120 molecules in Alzheimer’s research, the great hope for patients, families and society
  • The pharmaceutical industry’s plan to expand clinical trials in primary care
  • Health commitment to the pharmaceutical industry’s Strategic Plan to avoid losing 8,000 million euros

Contacta con nosotros


Tfno: +34 955.77.67.67
Fax: +34 955.77.65.56
info@distefar.net


Distefar del Sur
Sede Central

Distefar del Sur S.L.
Av. Umbrete, 58,
41110 Bollullos de la Mitación, Sevilla

Sede Madrid

Calle de Zurbano, 45, 28010 Madrid

CENTRAL

Pol. PIBO. Avda. de Gines, 14
+34 955 776 767 /+34 692 454 913
41110 Bollullos de la Mitación (Sevilla)

DELEGACIÓN MADRID

+34 674 575 115
28010 Madrid

Enlaces de interés

  • Aviso Legal
  • Política de privacidad
  • Política de cookies
  • Contacto

© 2023 Distefar del Sur SL. Todos los derechos reservados. agencianodo.com

  • Contact
  • Private Zone
  • Español
  • English

    [recaptcha]

    In accordance with the provisions of Regulation (EU) 2016/679 and Organic Law 3/2018 regarding Data Protection, we inform you that the data you provide in this form will be incorporated into a file owned by DISTEFAR DEL SUR, SL domiciled in the C / Umbrete 58, (Pol. Ind. Pibo), 41110 of Bollullos de la Mitación (Seville), in order to manage your request.

    In this regard, and if you wish to exercise your rights of access, rectification, cancellation, opposition, portability and limitation, please send a written communication to DISTEFAR DEL SUR, SL, to the address indicated above or to info@distefar.com, attaching copy of your National Identity Document or equivalent identification document.

    Basic information about Data Protection

     Epigraph

    Basic information Data Protection

    Responsable

    DISTEFAR DEL SUR, S.L.

    Purpose

    Process your inquiry / request
    Detailed information on Data Protection

    Legitimation

    Consent
    Detailed information on Data Protection

    Recipients

    It is not expected to carry out data communications to third parties, except legal obligation
    Transfers of data to third countries outside the European Union will not be carried out
    Detailed information on Data Protection

    Rights

    You have the right of access, rectification, deletion, portability of your data, as well as limitation or opposition to your treatment, as detailed in Detailed information on Data Protection

    Additional Information

    You can consult the additional and detailed information on data protection by clicking here Detailed information on Data Protection

    All the data requested / The fields marked with * in the form are mandatory, if not filled in DISTEFAR DEL SUR, S.L. will not be able to meet your request.